October 25, 2021
Establishing the Test-Retest Reliability and Minimal Detectable Change of the Multiple Sclerosis Resiliency Scale (MSRS)
Background: The Multiple Sclerosis Resiliency Scale (MSRS) is the first measure designed to assess the factors connected to resilience...
October 25, 2021
Identifying Behavioral Targets to Reduce Missed Multiple Sclerosis-Related Appointments: Potential Implications for Interventions
Background: Missed appointments without cancellation or no shows can cause disruptions in necessary healthcare services, which can be...
October 25, 2021
Concentration of Evobrutinib, a Brutons Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study
Background: Evobrutinib, a highly selective Brutons tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg...
Poster-Neurophysiology; Neuropsychology and Neuropsychiatry
October 25, 2021
Identifying Prospective Memory Deficits in MS with a Single Task from the Memory for Intentions Test: An IRT and ROC Analysis
Background: While many persons with multiple sclerosis (PwMS) have prospective memory (PM) issues, which can have an impact on everyday...
October 25, 2021
Health Resource Utilization Among Individuals with Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)
Background: The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) is a physician-based longitudinal registry of...
October 25, 2021
Neural Correlates of Hand Motor Function Revealed By Structural MR Imaging: A Smartphone-Based Remote Assessment Study in People with MS
Background: Regional gray matter pathology is associated with hand motor impairment in people with multiple sclerosis (PwMS). Objectives:...
Poster-Disease-modifying Therapy
October 25, 2021
Online Medical Education Increases Knowledge Among Neurologists of Safety Considerations for Disease Modifying Therapies in Multiple Sclerosis
Background: Disease modifying therapies (DMTs) have transformed the management of multiple sclerosis (MS). Patients can now live many years...
Poster-Disease-modifying Therapy
October 25, 2021
Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy
Background: B-cell depletion in patients with relapsing multiple sclerosis (RMS) using anti-CD20 monoclonal antibodies (mAbs) reduces...
Poster-Disease-modifying Therapy
October 25, 2021
Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties
Background: Siponimod, a potent and selective sphingosine 1-phosphate (S1P1,5) receptor modulator, is the first oral disease-modifying...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study
Background: Patients with relapsing-remitting multiple sclerosis (RRMS) often experience disease activity despite receiving a...